Achieve Life Sciences Inc (ACHV) Stock Price, Quote & News

Company Profile

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washing...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 210 2217

Website: www.achievelifesciences.com

Address:

22722 29th Dr. SE, Suite 100, Bothell, United States

BullJack Mar. 10 at 10:24 PM

Holding $DAVE $TTD and $ACHV TTD bears 🐻 drop your comments below plz.

0 · Reply

BullJack Mar. 10 at 8:03 PM

$ACHV bought some June $5 calls

0 · Reply

Faiq6925 Mar. 10 at 11:24 AM

$ACHV 👀

0 · Reply

AB5HUNNID Mar. 9 at 8:34 PM

$ACHV made some shmoney on $HIMS, time to relocate some funds to this hidden gem

0 · Reply

DragonAlgo Mar. 9 at 7:55 PM

🐉 $ACHV CALL — DragonAlgo® Signal Contract: ACHV CALL Expiry: 2026-06-18 | Strike: $5.00 | Type: CALL Option Plan (premium): Entry: $0.78 Stop: $0.56 TP1: $1.01 TP2: $1.32 TP3: $1.86 🔗 https://dragonalgo.com

1 · Reply

HarveySpecter20 Mar. 9 at 7:42 PM

$ACHV when ER?🧐

1 · Reply

BullJack Mar. 6 at 5:36 AM

$ACHV June 20 target FDA date. Gonna start some buys

0 · Reply

Crazy038 Mar. 6 at 1:11 AM

$ACHV

0 · Reply

V106GuY Mar. 5 at 1:45 PM

$ACHV

0 · Reply

DragonAlgo Mar. 5 at 3:20 AM

🐉 $ACHV CALL — DragonAlgo® Signal Contract: ACHV CALL Expiry: 2026-12-18 | Strike: $5.00 | Type: CALL Option Plan (premium): Entry: $1.57 Stop: $1.13 TP1: $2.05 TP2: $2.68 TP3: $3.78 Active momentum environment. 🔗 https://dragonalgo.com

0 · Reply

Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study

Feb 4, 2026, 8:57 PM EST - 4 weeks ago

Achieve Life Sciences: A Binary Bet With Cytisinicline And A Potential 2026 Launch

Feb 4, 2026, 2:43 AM EST - 4 weeks ago

Achieve Life Sciences: Could Be The Best 'Tobacco' Stock For 2026 - Strong Buy

Jan 30, 2026, 4:05 PM EST - 5 weeks ago

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

Jan 12, 2026, 8:47 AM EST - 2 months ago

Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer

Dec 17, 2025, 4:11 PM EST - 2 months ago

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

Nov 6, 2025, 3:26 PM EST - 4 months ago

Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:00 AM EST - 4 months ago

Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Nov 3, 2025, 8:30 AM EST - 4 months ago

Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation

Oct 29, 2025, 8:30 AM EDT - 4 months ago

Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025

Oct 20, 2025, 8:30 AM EDT - 5 months ago

Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

Oct 20, 2025, 7:15 AM EDT - 5 months ago

Achieve: Expedited Review Of Cytisinicline Sets The Stage For Development Expansion

Oct 17, 2025, 7:30 AM EDT - 5 months ago

Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation

Oct 2, 2025, 4:01 PM EDT - 5 months ago

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

Sep 22, 2025, 8:30 AM EDT - 6 months ago

Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline's Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD

Sep 18, 2025, 8:30 AM EDT - 6 months ago

Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer

Sep 11, 2025, 5:01 PM EDT - 6 months ago

Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer

Sep 3, 2025, 8:30 AM EDT - 6 months ago

Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation

Sep 2, 2025, 8:30 AM EDT - 6 months ago

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

Aug 21, 2025, 2:11 PM EDT - 7 months ago

Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years

Aug 8, 2025, 10:12 AM EDT - 7 months ago

Achieve Life Sciences, Inc. (ACHV) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:30 AM EDT - 7 months ago

Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Jul 29, 2025, 8:30 AM EDT - 8 months ago

Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference

Jul 24, 2025, 8:30 AM EDT - 8 months ago

Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025

Jul 7, 2025, 1:55 PM EDT - 8 months ago

Achieve Life Sciences: Nearing Commercialization Of A Best-In-Class Pharmaceutical Product For Smoking Cessation

Jun 30, 2025, 7:52 PM EDT - 9 months ago

Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters' Option to Purchase Additional Securities

Jun 26, 2025, 11:43 PM EDT - 9 months ago

Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering

Jun 26, 2025, 4:03 PM EDT - 9 months ago

Achieve Life Sciences Announces Proposed Underwritten Public Offering

Jun 26, 2025, 4:02 PM EDT - 9 months ago

Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades

OMC

Jun 3, 2025, 6:28 PM EDT - 10 months ago

Achieve Life Sciences: FDA Approval Not Assured, But Valuation Justifies Risk

May 28, 2025, 8:30 AM EDT - 10 months ago

Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 8:30 AM EDT - 10 months ago

Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake

May 13, 2025, 12:16 PM EDT - 10 months ago

Achieve Life Sciences, Inc. (ACHV) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:30 AM EDT - 10 months ago

Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program

May 6, 2025, 8:30 AM EDT - 11 months ago

Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

Apr 21, 2025, 11:19 AM EDT - 11 months ago

Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine

Mar 11, 2025, 2:52 PM EDT - 1 year ago

Achieve Life Sciences, Inc. (ACHV) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 7:30 AM EDT - 1 year ago

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

Mar 7, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference

Mar 6, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025

Feb 11, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Present at the Oppenheimer Healthcare Life Sciences Conference

Feb 10, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

Jan 10, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

Jan 7, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

Dec 9, 2024, 8:30 AM EST - 1 year ago

Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer

Dec 3, 2024, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA

Nov 25, 2024, 7:54 AM EST - 1 year ago

Smoking Cessation Pipeline Insight 2024, with Focus on Emerging Drugs Cytisinicline (Achieve Life Sciences), EMB-001(Embera Pharmaceuticals) and SBP-9330 (Camino Pharma)

Nov 9, 2024, 7:32 AM EST - 1 year ago

Achieve Life Sciences, Inc. (ACHV) Q3 2024 Earnings Call Transcript

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Achieve Life Sciences President and CMO, Dr. Cindy Jacobs, Speaks at FDA and NIH Smoking Cessation Public Meeting

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline

BullJack Mar. 10 at 10:24 PM

Holding $DAVE $TTD and $ACHV TTD bears 🐻 drop your comments below plz.

0 · Reply

BullJack Mar. 10 at 8:03 PM

$ACHV bought some June $5 calls

0 · Reply

Faiq6925 Mar. 10 at 11:24 AM

$ACHV 👀

0 · Reply

AB5HUNNID Mar. 9 at 8:34 PM

$ACHV made some shmoney on $HIMS, time to relocate some funds to this hidden gem

0 · Reply

DragonAlgo Mar. 9 at 7:55 PM

1 · Reply

HarveySpecter20 Mar. 9 at 7:42 PM

$ACHV when ER?🧐

1 · Reply

BullJack Mar. 6 at 5:36 AM

$ACHV June 20 target FDA date. Gonna start some buys

0 · Reply

Crazy038 Mar. 6 at 1:11 AM

$ACHV

0 · Reply

V106GuY Mar. 5 at 1:45 PM

$ACHV

0 · Reply

DragonAlgo Mar. 5 at 3:20 AM

0 · Reply

V106GuY Mar. 4 at 7:43 PM

$ACHV https://x.com/i/status/2029205275429736714

1 · Reply

rabbot Mar. 4 at 1:49 PM

$ACHV as a bagholder from over 5.50, today's news got me feeling like Booker T and Big E in they peak obsession FIVE FIVE FIVE FIVE FIVE

0 · Reply

MrTicker Mar. 4 at 1:10 PM

$ACHV Achieve Life Sciences Announces New Data On Cytisinicline As Smoking Cessation BENZINGA 7:07 AM ET 3/4/2026 Achieve also announces late-breaking survey data from ORCA-OL, demonstrating participant experience with extended cytisinicline use. These findings will be presented during the Society for Research on Nicotine & Tobacco (SRNT) 2026 Annual Meeting, March 4-7 in Baltimore, Maryland.

0 · Reply

TheTradeXchange Mar. 4 at 1:02 PM

$ACHV - Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study

0 · Reply

MrTicker Mar. 4 at 1:00 PM

$ACHV Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study GLOBENEWSWIRE 7:00 AM ET 3/4/2026

0 · Reply

bobtheknob Mar. 4 at 10:21 AM

$ACHV I’m not expecting any significant news with Q4 2025 CC. If there is any dilutive financing I’d expect it to happen soon after this earnings report. Otherwise the radio silence is for a reason, there could be some other positive developments signaled by FDA behind closed doors. In any case I expect a run up to PDUFA to start soon and we break out of the current trading range.

1 · Reply

DragonAlgo Mar. 3 at 1:59 PM

🐉 $ACHV CALL — DragonAlgo® Signal Contract: ACHV CALL Expiry: 2026-03-20 | Strike: $5.00 | Type: CALL Option Plan (premium): Entry: $0.26 Stop: $0.19 TP1: $0.34 TP2: $0.44 TP3: $0.62 🔗 https://dragonalgo.com

0 · Reply

HyperBulls Mar. 3 at 10:37 AM

$ACHV I think the company will be talking about positive developments on March 12th Earnings Day including the potential status of Sopharma and its second supplier, the FDA's inspection status, coupon usage, and expectations regarding the FDA and may be merges buyout opportunities after earning.

2 · Reply

markwall Mar. 2 at 9:16 AM

$ACHV Welp there goes the stock market, another war in the middle east started by USA/Israel, looks like it's not going according to plan. Hopefully an overall market correction does not derail Achieve.

3 · Reply

DragonAlgo Feb. 28 at 7:03 AM

🐉 $ACHV CALL — DragonAlgo® Signal Contract: ACHV CALL Expiry: 2026-06-18 | Strike: $5.00 | Type: CALL Option Plan (premium): Entry: $0.88 Stop: $0.63 TP1: $1.14 TP2: $1.49 TP3: $2.10 🔗 https://dragonalgo.com

0 · Reply

DragonAlgo Feb. 27 at 1:12 PM

🐉 $ACHV CALL — DragonAlgo® Signal Contract: ACHV CALL Expiry: 2026-03-20 | Strike: $5.00 | Type: CALL Option Plan (premium): Entry: $0.34 Stop: $0.24 TP1: $0.44 TP2: $0.58 TP3: $0.82 Momentum tape remains active. 🔗 https://dragonalgo.com

0 · Reply

Mtango Feb. 27 at 12:47 PM

$ACHV I may be reading too much between the tea leaves but Sopharma’s Q4 earnings and management report said nothing about litigation with ACHV. Does this mean the conflict has been resolved? Who knows! @They_Call_Me_Tater_Salad

1 · Reply

Market Cap	224.65M
Revenue (ttm)	0.00
Net Income (ttm)	-39.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.04

Volume	378,600
Avg Vol	621,060
Day's Range	N/A - N/A
Shares Out	53.23M
Stochastic %K	19%
Beta	1.81
Analysts	Strong Sell
Price Target	$15.57